Ibrutinib’s Success in CLL Treatment: Supported by Real World Data

⁤Final results are in from the EVIdeNCE study, which analyzed 309 chronic lymphocytic leukemia (CLL) patients in Italy treated with ibrutinib (Imbruvica; AbbVie/Pharmacyclics), reaffirming the efficacy and safety previously shown in clinical trials. ⁤⁤Despite a significant number of patients with cardiovascular comorbidities, these conditions did not affect the clinical outcomes. ⁤⁤Results showed impressive two-year retention (70.2%) and survival rates, with the best outcomes in first-line treatment. ⁤⁤Discontinuation due to adverse effects occurred in 29.8% of cases, with infections and cardiac events being the primary reasons. ⁤⁤The study underscores the importance of managing ibrutinib-related side effects to enhance patient outcomes. ⁤⁤This real-world data confirms ibrutinib as a valuable CLL therapy, particularly effective when administered early in the treatment sequence. ⁤

To read more, click here.

[Source: AJMC, April 24, 2024]